遗传因素与石棉相关疾病患者血清钙化蛋白水平的关系

IF 2.1 4区 医学 Q3 ONCOLOGY
Radiology and Oncology Pub Date : 2023-11-30 eCollection Date: 2023-12-01 DOI:10.2478/raon-2023-0061
Cita Zupanc, Alenka Franko, Danijela Strbac, Viljem Kovac, Vita Dolzan, Katja Goricar
{"title":"遗传因素与石棉相关疾病患者血清钙化蛋白水平的关系","authors":"Cita Zupanc, Alenka Franko, Danijela Strbac, Viljem Kovac, Vita Dolzan, Katja Goricar","doi":"10.2478/raon-2023-0061","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Asbestos exposure is associated with different asbestos-related diseases, including malignant mesothelioma (MM). MM diagnosis is confirmed with immunohistochemical analysis of several markers, including calretinin. Increased circulating calretinin was also observed in MM. The aim of the study was to determine if <i>CALB2</i> polymorphisms or polymorphisms in genes that can regulate calretinin expression are associated with serum calretinin levels or MM susceptibility.</p><p><strong>Subjects and methods: </strong>The study included 288 MM patients and 616 occupationally asbestos-exposed subjects without MM (153 with asbestosis, 380 with pleural plaques and 83 without asbestos-related disease). Subjects were genotyped for seven polymorphisms in <i>CALB2</i>, <i>E2F2</i>, <i>MIR335</i>, <i>NRF1</i> and <i>SEPTIN7</i> genes using competitive allele-specific polymerase chain reaction (PCR). Serum calretinin was determined with ELISA in 545 subjects. Nonparametric tests, logistic regression and receiver operating characteristic (ROC) curve analysis were used for statistical analysis.</p><p><strong>Results: </strong>Carriers of at least one polymorphic <i>CALB2</i> rs889704 allele had lower calretinin levels (P = 0.036). Carriers of two polymorphic <i>MIR335</i> rs3807348 alleles had higher calretinin (P = 0.027), while carriers of at least one polymorphic <i>NRF1</i> rs13241028 allele had lower calretinin levels (P = 0.034) in subjects without MM. Carriers of two polymorphic <i>E2F2</i> rs2075995 alleles were less likely to develop MM (odds ratio [OR] = 0.64, 95% confidence interval [CI] = 0.43-0.96, P = 0.032), but the association was no longer significant after adjustment for age (P = 0.093). Optimal serum calretinin cut-off values differentiating MM patients from other subjects differed according to <i>CALB2</i>, <i>NRF1</i>, <i>E2F2</i>, and <i>MIR335</i> genotypes.</p><p><strong>Conclusions: </strong>The results of presented study suggest that genetic variability could influence serum calretinin levels. These findings could contribute to a better understanding of calretinin regulation and potentially to earlier MM diagnosis.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 4","pages":"473-486"},"PeriodicalIF":2.1000,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690752/pdf/","citationCount":"0","resultStr":"{\"title\":\"The association of genetic factors with serum calretinin levels in asbestos-related diseases.\",\"authors\":\"Cita Zupanc, Alenka Franko, Danijela Strbac, Viljem Kovac, Vita Dolzan, Katja Goricar\",\"doi\":\"10.2478/raon-2023-0061\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Asbestos exposure is associated with different asbestos-related diseases, including malignant mesothelioma (MM). MM diagnosis is confirmed with immunohistochemical analysis of several markers, including calretinin. Increased circulating calretinin was also observed in MM. The aim of the study was to determine if <i>CALB2</i> polymorphisms or polymorphisms in genes that can regulate calretinin expression are associated with serum calretinin levels or MM susceptibility.</p><p><strong>Subjects and methods: </strong>The study included 288 MM patients and 616 occupationally asbestos-exposed subjects without MM (153 with asbestosis, 380 with pleural plaques and 83 without asbestos-related disease). Subjects were genotyped for seven polymorphisms in <i>CALB2</i>, <i>E2F2</i>, <i>MIR335</i>, <i>NRF1</i> and <i>SEPTIN7</i> genes using competitive allele-specific polymerase chain reaction (PCR). Serum calretinin was determined with ELISA in 545 subjects. Nonparametric tests, logistic regression and receiver operating characteristic (ROC) curve analysis were used for statistical analysis.</p><p><strong>Results: </strong>Carriers of at least one polymorphic <i>CALB2</i> rs889704 allele had lower calretinin levels (P = 0.036). Carriers of two polymorphic <i>MIR335</i> rs3807348 alleles had higher calretinin (P = 0.027), while carriers of at least one polymorphic <i>NRF1</i> rs13241028 allele had lower calretinin levels (P = 0.034) in subjects without MM. Carriers of two polymorphic <i>E2F2</i> rs2075995 alleles were less likely to develop MM (odds ratio [OR] = 0.64, 95% confidence interval [CI] = 0.43-0.96, P = 0.032), but the association was no longer significant after adjustment for age (P = 0.093). Optimal serum calretinin cut-off values differentiating MM patients from other subjects differed according to <i>CALB2</i>, <i>NRF1</i>, <i>E2F2</i>, and <i>MIR335</i> genotypes.</p><p><strong>Conclusions: </strong>The results of presented study suggest that genetic variability could influence serum calretinin levels. These findings could contribute to a better understanding of calretinin regulation and potentially to earlier MM diagnosis.</p>\",\"PeriodicalId\":21034,\"journal\":{\"name\":\"Radiology and Oncology\",\"volume\":\"57 4\",\"pages\":\"473-486\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2023-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690752/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiology and Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2478/raon-2023-0061\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/12/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/raon-2023-0061","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:石棉暴露与不同的石棉相关疾病有关,包括恶性间皮瘤(MM)。MM的诊断是通过免疫组化分析几种标志物,包括calretinin。在MM中也观察到循环calretinin增加。该研究的目的是确定CALB2多态性或调节calretinin表达的基因多态性是否与血清calretinin水平或MM易感性相关。研究对象和方法:该研究包括288名MM患者和616名无MM的职业石棉暴露者(153名患有石棉肺,380名患有胸膜斑块,83名无石棉相关疾病)。采用竞争性等位基因特异性聚合酶链反应(PCR)对受试者CALB2、E2F2、MIR335、NRF1和SEPTIN7基因的7个多态性进行基因分型。采用ELISA法测定545例受试者血清calretinin。采用非参数检验、logistic回归和受试者工作特征(ROC)曲线分析进行统计分析。结果:携带至少一个多态CALB2 rs889704等位基因的人calretinin水平较低(P = 0.036)。携带2个多态MIR335 rs3807348等位基因的人群罹患MM的calretinin水平较高(P = 0.027),携带至少1个多态NRF1 rs13241028等位基因的人群罹患MM的calretinin水平较低(P = 0.034)。携带2个多态E2F2 rs2075995等位基因的人群罹患MM的可能性较低(优势比[OR] = 0.64, 95%可信区间[CI] = 0.43-0.96, P = 0.032),但调整年龄后相关性不再显著(P = 0.093)。根据CALB2、NRF1、E2F2和MIR335基因型不同,MM患者与其他受试者的最佳血清calretinin临界值不同。结论:本研究结果提示遗传变异可能影响血清calretinin水平。这些发现有助于更好地理解钙维素的调节,并可能有助于早期MM的诊断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The association of genetic factors with serum calretinin levels in asbestos-related diseases.

Background: Asbestos exposure is associated with different asbestos-related diseases, including malignant mesothelioma (MM). MM diagnosis is confirmed with immunohistochemical analysis of several markers, including calretinin. Increased circulating calretinin was also observed in MM. The aim of the study was to determine if CALB2 polymorphisms or polymorphisms in genes that can regulate calretinin expression are associated with serum calretinin levels or MM susceptibility.

Subjects and methods: The study included 288 MM patients and 616 occupationally asbestos-exposed subjects without MM (153 with asbestosis, 380 with pleural plaques and 83 without asbestos-related disease). Subjects were genotyped for seven polymorphisms in CALB2, E2F2, MIR335, NRF1 and SEPTIN7 genes using competitive allele-specific polymerase chain reaction (PCR). Serum calretinin was determined with ELISA in 545 subjects. Nonparametric tests, logistic regression and receiver operating characteristic (ROC) curve analysis were used for statistical analysis.

Results: Carriers of at least one polymorphic CALB2 rs889704 allele had lower calretinin levels (P = 0.036). Carriers of two polymorphic MIR335 rs3807348 alleles had higher calretinin (P = 0.027), while carriers of at least one polymorphic NRF1 rs13241028 allele had lower calretinin levels (P = 0.034) in subjects without MM. Carriers of two polymorphic E2F2 rs2075995 alleles were less likely to develop MM (odds ratio [OR] = 0.64, 95% confidence interval [CI] = 0.43-0.96, P = 0.032), but the association was no longer significant after adjustment for age (P = 0.093). Optimal serum calretinin cut-off values differentiating MM patients from other subjects differed according to CALB2, NRF1, E2F2, and MIR335 genotypes.

Conclusions: The results of presented study suggest that genetic variability could influence serum calretinin levels. These findings could contribute to a better understanding of calretinin regulation and potentially to earlier MM diagnosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Radiology and Oncology
Radiology and Oncology ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
CiteScore
4.40
自引率
0.00%
发文量
42
审稿时长
>12 weeks
期刊介绍: Radiology and Oncology is a multidisciplinary journal devoted to the publishing original and high quality scientific papers and review articles, pertinent to diagnostic and interventional radiology, computerized tomography, magnetic resonance, ultrasound, nuclear medicine, radiotherapy, clinical and experimental oncology, radiobiology, medical physics and radiation protection. Therefore, the scope of the journal is to cover beside radiology the diagnostic and therapeutic aspects in oncology, which distinguishes it from other journals in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信